Erudio Healtherudio.com
Drug
Sorafenib trials: what clinicians said in public
No HCP commentary report on a trial studying sorafenib yet. Erudio has found public clinician commentary on 10 clinical trials studying sorafenib, including CheckMate 9DW, IMbrave150, RTOG 1112 and TIVO-3. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IMbrave150 NCT03434379 · Hoffmann-La Roche DeepView → | untreated locally advanced or metastatic hepatocellular carcinoma | Phase 3 | Deep | View | |||
| CheckMate 9DW NCT04039607 · Bristol-Myers Squibb DeepView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| RTOG 1112 NCT01730937 · Radiation Therapy Oncology Group DeepView → | advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| TIVO-3 NCT02627963 · AVEO Pharmaceuticals, Inc. DeepView → | relapsed/refractory advanced renal cell carcinoma | Phase 3 | Deep | View | |||
| IMbrave251 NCT04770896 · Hoffmann-La Roche DeepView → | hepatocellular carcinoma previously treated with atezolizumab and bevacizumab | Phase 3 | Deep | View | |||
| COSMIC-312 NCT03755791 · Exelixis DeepView → | treatment-naive advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| CheckMate 459 NCT02576509 · Bristol-Myers Squibb DeepView → | first-line advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| RATIONALE-301 NCT03412773 · BeiGene DeepView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| HIMALAYA NCT03298451 · AstraZeneca FocusedView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Focused | View | |||
| GroundBBreaker 301 NCT07836530 · BeOne Medicines FocusedView → | Not given | Phase 3 | Focused | View | |||